Oculis Holding AG (FRA:CR5) Interest Expense: €-0.96 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CR5 Oculis Holding AG FRA:CR5
32 GF Score
Price €10.35
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Interest Expense?

Oculis Holding AG FRA:CR5 32 Interest Expense is €-0.96 Mil as of Jun. 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oculis Holding AG's interest expense for the three months ended in Jun. 2026 was € -0.34 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.96 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oculis Holding AG's Operating Income for the three months ended in Jun. 2026 was € -25.59 Mil. Oculis Holding AG's Interest Expense for the three months ended in Jun. 2026 was € -0.34 Mil. Oculis Holding AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oculis Holding AG  (FRA:CR5) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oculis Holding AG's Interest Expense for the three months ended in Jun. 2026 was €-0.34 Mil. Its Operating Income for the three months ended in Jun. 2026 was €-25.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was €1.95 Mil.

Oculis Holding AG's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Oculis Holding AG did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Oculis Holding AG Interest Expense Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG Interest Expense Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -4.92 -6.53 -1.39 -0.68 -0.89

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.17 -0.26 -0.19 -0.34
FRA:CR5
32GF Score
Oculis Holding AG FRA:CR5
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.96 Mil mean?
Oculis Holding AG (FRA:CR5) has a Interest Expense of €-0.96 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Oculis Holding AG and its competitors.
Is Oculis Holding AG's Interest Expense too high?
Oculis Holding AG's current Interest Expense is €-0.96 Mil. Overall, Oculis Holding AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Interest Expense compare to RIGL and GYRE?
Oculis Holding AG's Interest Expense of €-0.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current Interest Expense is €-0.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current Interest Expense of €-0.96 Mil. The current Interest Expense is €-0.96 Mil. Oculis Holding AG's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current Interest Expense is €-0.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
32GF Score

Get the complete analysis for FRA:CR5

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.35
Price